No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 37 of the 40 quarters in the window, leaving 3 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Aldeyra The (ALDX) stock was $0.98 as of Oct 6, 2026, 10:05 AM EDT, up 6.01% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.8% · 3-year avg -45.9%/yr · 5-year avg -36.5%/yr
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Biotechnology · Lexington, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.11
Revenue Est.
$2.50M
Last Quarter Results
EPS
$-0.09
vs Estimate
$-0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALDX | $59.07M | $0.98 | +6.01% | -83.77% | -36.54% | -18.91% | N/A |
| 2INKT | $59.32M | $11.91 | -2.40% | -18.69% | N/A | N/A | vs ALDX |
| 3GUTS | $59.56M | $4.50 | -1.21% | -75.32% | N/A | N/A | vs ALDX |
| 4ACET | $60.30M | $6.45 | -0.31% | -51.37% | -44.24% | N/A | vs ALDX |
| 5BOLD | $57.76M | $2.57 | -1.15% | +110.63% | N/A | N/A | vs ALDX |
| 6MDAI | $56.33M | $1.77 | +4.73% | -24.11% | -29.57% | N/A | vs ALDX |
N/A
$0.00
vs Estimate
$31.33M
Consensus Rating
Based on 5 analysts
Average Price Target
$6.60
+574.0% upside
Low
$2.00
Current
$0.98
High
$13.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.09 | $-0.09 | $-0.09 | 2 |
| Quarter ending Dec 2026 | $-0.10 | $-0.10 | $-0.10 | 2 |
| Quarter ending Mar 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Quarter ending Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.47 | $-0.34 | $-0.21 | 3 |
| FY 2027 | $-0.38 | $-0.28 | $-0.17 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.50M | $2.50M | $2.50M | 1 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $885709.00 | $1.25M | $1.61M | 2 |
| FY 2027 | $5.95M | $8.40M | $10.85M | 3 |
